FDA Peptide Approval? BPC-157, TB-500 and MOTS-c Explained
FDA peptide approval is not what happened this week. On 23 July 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend that BPC-157 be added to a list of substances compounding pharmacies are permitted to use. That is not approval. It is not a final decision. And it went against the recommendation of the FDA’s own scientists.
The headlines this week have compressed three separate things into one. Understanding the difference matters, because each carries a completely different legal weight.
What did the FDA advisory committee actually vote on?
The Pharmacy Compounding Advisory Committee (PCAC) met on 23 and 24 July 2026 to consider seven peptides for inclusion on the Section 503A Bulk Drug Substances List. That list governs which raw substances state-licensed compounding pharmacies may legally use when preparing a medicine against an individual prescription.
Inclusion on that list is not drug approval. None of the seven peptides is an FDA-approved drug, and the vote did not change that for any of them. A substance can sit on the 503A list without ever having completed the clinical trial programme an approved drug requires.
The committee reviewed each peptide against a specific nominated indication, not as a blanket judgement on the compound.
Which peptides were reviewed, and how did the votes go?
Over the two days the committee recommended six of the seven peptides for the list. Emideltide was the only one it declined.
| Peptide | Indication FDA reviewed | Committee vote |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6, one abstention — recommended |
| KPV | Inflammatory conditions | Recommended |
| TB-500 | Wound healing | Recommended |
| MOTS-c | Obesity and osteoporosis | Recommended |
| Epitalon | Reviewed 24 July | Recommended |
| Semax | Cerebral ischemia, migraine | 8–5, one abstention — recommended |
| Emideltide (DSIP) | Insomnia | 7–4, one abstention — not recommended |
The indications listed above are the specific uses FDA scientists assessed during the review. They are recorded here as a matter of public record and do not describe any use of the research materials sold on this site.
Why did FDA scientists oppose the recommendation?
Before the meeting, FDA’s own briefing documents reached the same conclusion for all seven substances: do not add them to the list. The agency applied the four-factor framework set out in 21 CFR 216.23(c), covering physical and chemical characterisation, safety, evidence of effectiveness, and historical use.
The recurring findings were that the substances are not well characterised, that human evidence of effectiveness is thin or absent for the proposed routes of administration, and that immunogenicity risk has not been assessed. For KPV, TB-500 and MOTS-c, FDA reported no human clinical evidence at all. For BPC-157, the available studies were small, uncontrolled or contradictory.
The committee then voted to recommend six of the seven anyway. Members voting in favour generally judged the risks to be low and argued that decisions about an individual patient’s treatment belong between a doctor and that patient. Those voting against were concerned that listing a substance would create a false impression that it had been evaluated to the standard of an approved drug. That the panel rejected emideltide, rather than waving all seven through, indicates the votes were contested on the merits.
Is the vote binding?
No. PCAC recommendations are advisory. The FDA is not obliged to follow them, though it usually does, and a recommendation from the committee is not the same as a decision from the agency. Six favourable votes this week are six recommendations, not six approvals.
Even where the agency accepts a recommendation, the substance is only added to the 503A list through formal notice-and-comment rulemaking. That process has historically taken twelve months or more. Nothing changes for compounding pharmacies until a final rule is published, and nothing changes for anyone else at all.
How did we get here?
| Date | What happened |
|---|---|
| 2013 | The Drug Quality and Security Act creates the 503A and 503B compounding frameworks |
| January 2022 | WADA adds BPC-157 to its prohibited list |
| September 2023 | FDA places a batch of popular peptides, including BPC-157 and TB-500, into Category 2 of the interim 503A list, the designation for substances that may present significant safety risks. Compounding pharmacies can no longer lawfully prepare them |
| February 2026 | HHS signals an intention to revisit the 2023 classifications |
| April 2026 | FDA removes twelve peptides from Category 2 after the original nominators withdraw their nominations. The substances move into review rather than onto the permitted list |
| 23–24 July 2026 | PCAC reviews seven of the twelve and recommends six. The remaining five are scheduled for a separate meeting before the end of February 2027 |
What is the 503A Bulks List?
The interim policy sorts nominated substances into three groups while FDA evaluates them.
- Category 1: under evaluation. FDA does not intend to take enforcement action against pharmacies compounding with these during the review.
- Category 2: raises significant safety concerns. Effectively blocks compounding.
- Category 3: nominated without adequate supporting information.
Removal from Category 2 is not the same as addition to the permitted list. Between April and now, the seven peptides have sat in neither position.
Are these peptides now legal to buy?
The vote changes nothing about how these compounds are supplied today. It concerns one specific channel, prescription compounding by licensed pharmacies inside the United States, and that channel is not open yet.
The research materials sold on this site are supplied strictly for laboratory research use and are not for human or veterinary use. That is unchanged and unaffected by this week’s proceedings.
Does this change anything outside the United States?
No. The 503A framework is a United States statutory scheme administered by the FDA. It does not affect the regulatory position in the United Kingdom, the European Union or anywhere else. UK research suppliers operate under a separate framework entirely.
Are BPC-157 and TB-500 still banned in sport?
Yes. Both remain on the World Anti-Doping Agency prohibited list, and this week’s vote has no bearing on that. WADA sets its own list independently of national medicines regulators. Any tested athlete remains subject to it.
What this means for the future of peptide regulation
The significance of this week is procedural rather than scientific. A committee recommended, against its own agency’s technical advice, that a group of compounds with little completed human trial data be made available through a regulated prescription channel. Whether FDA accepts those recommendations, and how it words any subsequent rule, will set the pattern for the five peptides due for review before the end of February 2027.
What has not changed is the underlying evidence base. Most of the research on these compounds remains preclinical, and the committee vote did not add a single study to it.
Further reading
For the research background on the two compounds at the centre of this week’s coverage, see our guides on BPC-157 and tendon repair and the Wolverine stack.
Research materials referenced in this article: BPC-157, TB-500, BPC-157 and TB-500 together, and MOTS-c.
Sources
- FDA Pharmacy Compounding Advisory Committee meeting materials, 23–24 July 2026
- FiercePharma, PCAC Day 2 vote results
- Orrick, FDA Peptide Compounding Vote analysis
- 21 CFR 216.23, evaluation criteria for bulk drug substances
- World Anti-Doping Agency Prohibited List
All products supplied by Pro Peptides Plus are intended for laboratory research use only. They are not medicines, are not for human or veterinary consumption, and nothing in this article should be read as describing their use.